Dr. Bannerji on Ongoing Research With REGN1979 in Non-Hodgkin Lymphoma
April 23rd 2020Rajat Bannerji, MD, PhD, hematologist/oncologist and chief of hematologic malignancies at the Rutgers Cancer Institute of New Jersey, discusses ongoing research with the bispecific antibody REGN1979 in non-Hodgkin lymphoma (NHL).
Read More
Dr. Bannerji on the Clinical Activity of the Bispecific Antibody REGN1979 in NHL
January 31st 2020Rajat Bannerji, MD, PhD, hematologist/oncologist and chief of hematologic malignancies at the Rutgers Cancer Institute of New Jersey, discusses the clinical activity of the bispecific antibody REGN1979 in patients with non-Hodgkin lymphoma (NHL).
Read More
Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist
Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer
Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC
2 Commerce Drive
Cranbury, NJ 08512